About
2.02USD-0.00 -0.25%
Closed • Updated at 07:41 GMT+00:00Market Cap$4.87M
Volume1.9K
Beta1.04
RSI41.06
Gross Margin13.00%
Bionexus Gene Lab Corp — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 11 2026
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
Feb 23 2026
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
Jan 28 2026
BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market
Dec 3 2025
BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™
Dec 2 2025
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization
Recent Videos

2025-07-01 04:52:02 BGLC Level 2 and Time & Sales
Apr 28, 2026

My BioNexus Gene Lab Corp Strategy Insight from Latest Filing
Mar 20, 2026

My Takeaway on BioNexus Gene Lab Corp's Executive Shake-Up
Dec 27, 2025

My Take on B.I.O. Nexus Gene Lab's Ethereum & Biotech Pivot
Nov 20, 2025
Community Chat
Ask AI
Try asking
Translate